physician departure

The purpose of this study is to assess changes of bone mineral density (BMD) at 12 months during the therapeutic management of patients with lymphoma.

Inclusion Criteria:

• Subjects aged 18 to 80 with lymphoma,
• Histological diagnosis of Hodgkin's lymphoma (HL) or non-Hodgkin lymphoma (NHL) of follicular or aggressive (large cell or other),
• Patients who have not yet started their chemotherapy or who have started for less than a month
• Patient has signed informed consent.

Exclusion Criteria:

• Pathological fractures at the time of initial diagnosis of lymphoma,
• Compression of neurological epidural,
• Patients receiving treatment for osteoporosis (including bisphosphonates, selective modulators of estrogen receptor, calcitonin and parathyroid hormone Teriparatide).
• Discovery of osteoporosis or osteopenia fracture during the initial evaluation requiring the establishment of an osteoporosis treatment,
• Radiotherapy to the lumbar spine or hip studied,
• Location of bone lymphoma in the lumbar spine or hip studied,
• History of disorders affecting bone metabolism (prostate cancer with androgen, stomach cancer, hyperparathyroidism, hyperthyroidism, uncontrolled ...)
• A person incapable of giving consent personally,
• Pregnant or breastfeeding women,
• Protected Person (under guardianship)
• Patient not affiliated with a social security system.